Catalent Expert To Discuss The Effect Of Immunoglobulin




Catalent Expert to Discuss the Effect of Immunoglobulin G Subclass or Allotype on Mammalian Cell Line Productivity at HAH 2011

Somerset, NJ – November 3, 2011 – Gregory T. Bleck, Ph.D., Research and Development Platform Director, Biologics, at Catalent Pharma Solutions is to present at the 16th International Human Antibodies & Hybridomas (HAH) meeting in Cannes, France.  Dr. Bleck’s presentation entitled “Effect of IgG Subclass or Allotype on the Ability to Generate a High Expressing Mammalian Cell Line and High Yielding Antibody Production Process Delivering Biologics” will take place on Tuesday, November 8, 2011.

Dr. Bleck will discuss how Catalent’s proprietary GPEx® technology, a versatile protein expression system capable of transferring genes of interest into a wide variety of mammalian host cells, was assessed to see how IgG allotype or subclasses impacted cell line productivity and the efficiency of this protein manufacturing process.

For more information on this event, please visit: www.meetingsmanagement.com .

For an interview with Dr. Bleck, please contact Patricia McGee or Chris Halling at media@catalent.com .

Dr. Bleck joined Catalent in 1998 as Director of Molecular Biology & Transgenics.  He has a broad background in Molecular Biology and Transgenic animals with 12 year’s experience within the organization.  Dr. Bleck holds a Bachelor’s degree in Dairy Science and a Doctorate in Endocrinology-Reproductive Physiology from the University of Wisconsin-Madison. He performed postdoctoral work at the University of Illinois-Urbana working in the areas of gene regulation and expression. Greg has published more than 55 research papers and co-authored chapters in three books.

About Catalent

From drug and biologic development services to delivery technologies to supply solutions, Catalent Pharma Solutions has the deepest expertise, the broadest offerings and the most unique technologies in the industry. With over 75 years of experience, Catalent helps customers get more molecules to market faster, enhance product performance, and provide superior, reliable manufacturing and packaging solutions. Catalent employs more than 8,000 people at 20+ facilities worldwide and in fiscal year 2011 generated more than $1.6 billion in annual revenue. Catalent is headquartered in Somerset, NJ.

more products. better treatments. reliably supplied.™